Zorifertinib

Warnings and Precautions

Skin and diarrhoea: these are the side effects most people notice. In EVEREST, 92.7% of patients had a rash or acne-like skin reaction (severe in 30.5%) and 64.5% had diarrhoea (severe in 13.2%). Gentle skin care, sun protection and early anti-diarrhoea treatment help a lot, and the dose can be paused or reduced.

• Liver tests: raised liver enzymes were very common (AST 72.3%, ALT 68.2%), mostly mild. Liver tests are checked regularly, and treatment is paused or reduced if the levels climb too high.
• Heart rhythm (QTc): QTc prolongation was seen in 14.1% (severe in 4.1%). An ECG and blood salts such as potassium and magnesium are checked before and during treatment. Low potassium was reported in 29.1%.
• Mouth, nails and appetite: mouth sores (39.5%), nail-fold infection (30.0%) and loss of appetite (41.8%) were also frequent.
• Lung inflammation (ILD): no confirmed cases were seen among 250 patients on the 200 mg dose, but it is a known risk with this type of medicine. Report new or worsening cough, breathlessness or fever at once. If ILD is confirmed, the medicine is stopped for good.
• Other medicines: strong CYP3A4 inducers or inhibitors can change the level of this medicine in the blood and should be avoided. Give your doctor a full list, including herbal products.
• Pregnancy: it can harm an unborn baby and must not be used in pregnancy. Both men and women should use effective contraception during treatment and for 3 months after the last dose, and breastfeeding should stop during treatment and for at least 3 months afterwards.

Overall: in the trial, 50.9% of patients needed a pause in treatment and 50.0% had the dose lowered because of side effects, while 7.3% stopped permanently. Safety in children under 18 has not been established.

How to Access Zorifertinib in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Zorifertinib to India?

The tablets can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:

• A valid prescription from a qualified medical oncologist
• Diagnostic reports, including the biopsy report, the EGFR mutation test (exon 19 deletion or L858R) and brain MRI or CT showing the metastases
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

Once we have received and checked a valid prescription and, where needed, an import permit.

Is Zorifertinib available in India?

No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.

Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. For other EGFR lung cancer situations, see our pages on Zegfrovy and Lazcluze.

It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.

Sourcing & Delivery

NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. Each bottle holds 28 tablets, so at the usual dose of two 100 mg tablets twice a day, one bottle of 100 mg tablets lasts one week. We plan supply month by month so treatment is not interrupted. The label says to keep the bottle tightly closed and below 30°C, and the tablets travel in their sealed original bottles under temperature-controlled shipping. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.

For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.

Availability Across Major Cities in India

Patients across India can access this medicine through regulated import pathways, with delivery arranged to the patient or the treating hospital on a valid oncologist's prescription.

Delhi

Large cancer centres in Delhi treat lung cancer patients from across North India, and our New Delhi dispatch point means the tablets can reach them quickly.

Mumbai

Oncologists in Mumbai can request the medicine for a named patient once the EGFR report and brain scans are shared.

Bangalore

Patients in Bangalore can have monthly supplies delivered to their home or to the hospital pharmacy.

Chennai

A major referral hub for lung cancer in South India, where many patients are already treated for brain metastases.

Hyderabad

We plan each month's bottles ahead so there is no gap between supplies.

Kolkata

Patients in Kolkata and the eastern states can use the same documented import route, with updates at every stage.

Pune

The treating oncologist can send us the prescription and test reports to start the import.

Ahmedabad

Oncologists in Ahmedabad can coordinate access for patients whose cancer has spread to the brain.

Jaipur

Patients across Rajasthan can receive the tablets without travelling, as long as the import is in their name.

Chandigarh

Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the patient or the treating hospital.

Lucknow

We coordinate delivery for patients treated at public and private cancer hospitals across Uttar Pradesh.

Kochi

Patients across Kerala can have their supply delivered to Kochi and nearby cities.

Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.